ARK Investment Management’s founder, CEO, and Chief Investment Officer is Catherine Duddy Wood. Wood had two of her funds included in the top ten largest funds managed by women in March 2021. She mostly invests in firms that have products with significant long-term growth potential. Tesla, Inc. has seen its stock rise by 248 percent in the last year. ARK Investment reduced its holdings in Taiwan Semiconductor Manufacturing Company Limited to 397,524 shares, a reduction of 91 percent. The company’s April revenue increased 16 percent year over year but fell 13.8 percent month over month to NT$111.315 billion. Apple Inc. was also reduced by 35% to 594,039 shares, according to ARK Investment.
Insider Monkey gives a list of the 10 best pharmaceutical stocks to buy according to Cathie Wood. Over the last year, investors have received a 40 percent return on their investment in Veracyte stock. In the first quarter of 2021, the company recorded revenue of $36.7 million, up 18% year over year. With 2.97 billion shares worth more than $160 million, Matrix Capital Management is the largest shareholder in Veracyte. Intellia Therapeutics, Inc. was founded in 2014 and is the ninth-best pharmaceutical stock to purchase on the list. Over the last year, the company’s stock has returned more than 253 percent to investors. Cathie Wood’s hedge fund owns about 5 million shares in the firm, valued at about $231 million. In the last few months, ARK activity on the Ionis stock has surged by 114%. Invitae Corporation is a medical genetics firm that makes use of genetic data in healthcare. According to Cathie Wood, it is ranked seventh on the list of the top ten pharmaceutical stocks to purchase. Over the last year, the company’s stock has returned more than 62 percent to investors. With 15.75 million shares worth more than $601 million, Baker Bros. Advisors is the largest shareholder in Invitae. Fate Therapeutics, Inc. is a company that develops cellular immunotherapies for cancer and immunological diseases. During the past year, investors have received a return of more than 129 percent on their investment in Fate stock. According to Cathie Wood, it is ranked sixth on the list of the top ten pharmaceutical stocks to purchase. For more details, click 10 Best Pharmaceutical Stocks to Buy According to Cathie Wood.
